NICE rejects Novartis' Afinitor, but OKs GSK's Revolade, InterMune's Esbriet PharmaTimes According to Novartis, Afinitor (everolimus) is the first new licensed therapeutic approach in fifteen years offering substantial impact on hormone responsive advanced breast cancer, which affects over 30,000 women in the UK. The gold standard of care ... Positive NICE news for GSK's Revolade and InterMune's Esbriet |
